PL2324113T3 - Cząstki wirusopodobne zawierające złożone kapsydowe sekwencje aminokwasowe do zwiększonej reaktywności krzyżowej - Google Patents

Cząstki wirusopodobne zawierające złożone kapsydowe sekwencje aminokwasowe do zwiększonej reaktywności krzyżowej

Info

Publication number
PL2324113T3
PL2324113T3 PL09805653T PL09805653T PL2324113T3 PL 2324113 T3 PL2324113 T3 PL 2324113T3 PL 09805653 T PL09805653 T PL 09805653T PL 09805653 T PL09805653 T PL 09805653T PL 2324113 T3 PL2324113 T3 PL 2324113T3
Authority
PL
Poland
Prior art keywords
virus
particles
amino acid
acid sequences
cross reactivity
Prior art date
Application number
PL09805653T
Other languages
English (en)
Polish (pl)
Inventor
Charles Richardson
Robert Bargatze
Joel Haynes
Bryan Steadman
Original Assignee
Takeda Vaccines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines, Inc. filed Critical Takeda Vaccines, Inc.
Publication of PL2324113T3 publication Critical patent/PL2324113T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL09805653T 2008-08-08 2009-08-10 Cząstki wirusopodobne zawierające złożone kapsydowe sekwencje aminokwasowe do zwiększonej reaktywności krzyżowej PL2324113T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8750408P 2008-08-08 2008-08-08
US21860309P 2009-06-19 2009-06-19
EP09805653.4A EP2324113B8 (en) 2008-08-08 2009-08-10 Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
PCT/US2009/053249 WO2010017542A1 (en) 2008-08-08 2009-08-10 Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity

Publications (1)

Publication Number Publication Date
PL2324113T3 true PL2324113T3 (pl) 2018-08-31

Family

ID=41664003

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09805653T PL2324113T3 (pl) 2008-08-08 2009-08-10 Cząstki wirusopodobne zawierające złożone kapsydowe sekwencje aminokwasowe do zwiększonej reaktywności krzyżowej

Country Status (14)

Country Link
US (2) US8841120B2 (enExample)
EP (2) EP3382011A1 (enExample)
JP (3) JP5852883B2 (enExample)
KR (2) KR101793161B1 (enExample)
CN (2) CN104911154A (enExample)
AU (1) AU2009279456B2 (enExample)
CA (1) CA2733589C (enExample)
DK (1) DK2324113T3 (enExample)
ES (1) ES2668836T3 (enExample)
HK (1) HK1215051A1 (enExample)
NO (1) NO2324113T3 (enExample)
PL (1) PL2324113T3 (enExample)
SG (1) SG2013057732A (enExample)
WO (1) WO2010017542A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044198A4 (en) * 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc CHIMERIC INFLUENZA VIRUS TYPE PARTICLES
HUE032422T2 (en) 2006-09-29 2017-09-28 Takeda Vaccines Inc Norovirus vaccine preparations
CA2683977C (en) * 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
AU2009279456B2 (en) 2008-08-08 2015-02-05 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN103154242B (zh) * 2010-07-06 2015-09-30 诺华股份有限公司 诺如病毒衍生的免疫原性组合物和方法
EA029470B1 (ru) * 2011-07-11 2018-03-30 Такеда Вэксинс, Инк. Способ стимулирования формирования защитного иммунитета против норовируса
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
JP6567824B2 (ja) * 2011-10-12 2019-08-28 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
WO2014165291A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Improved vaccines for human papilloma virus and methods for using the same
JP6479305B2 (ja) 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
JP2015015931A (ja) 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
US10524493B2 (en) * 2013-09-16 2020-01-07 The Johns Hopkins University Compositions and methods for preventing or relieving symptoms of infections
SG10202107054TA (en) 2013-10-03 2021-08-30 Takeda Vaccines Inc Methods of detection and removal of rhabdoviruses from cell lines
IL276210B2 (en) 2013-11-29 2024-01-01 Inovio Pharmaceuticals Inc Mers-cov vaccine
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CA3000329A1 (en) * 2015-08-28 2017-03-09 Ology Bioservices, Inc. Norovirus vaccine
EP3341018A1 (en) 2015-08-28 2018-07-04 Wisconsin Alumni Research Foundation Generation of infectious influenza viruses from virus-like particles
JP6920694B2 (ja) * 2015-12-04 2021-08-18 シアメン ユニバーシティＸｉａｍｅｎ Ｕｎｉｖｅｒｓｉｔｙ ヒトパピローマウイルスタイプ１１のｌ１タンパク質の突然変異
AU2017221444B2 (en) 2016-02-19 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Improved influenza B virus replication for vaccine development
EP3464647A4 (en) * 2016-06-03 2020-01-01 Quest Diagnostics Investments LLC METHODS FOR THE DETECTION OF NOROVIRUS
CA3056812C (en) * 2017-03-23 2022-11-29 Medicago Inc. Norovirus fusion proteins and vlps comprising norovirus fusion proteins
JP6877722B2 (ja) 2017-03-31 2021-05-26 国立大学法人 東京大学 ノロウイルス抗体
JP6795468B2 (ja) * 2017-07-14 2020-12-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
WO2019079594A1 (en) * 2017-10-18 2019-04-25 The University Of North Carolina At Chapel Hill METHODS AND COMPOSITIONS FOR VACCINES AGAINST NOVOVIRUS AND DIAGNOSIS OF NOVOVIRUS
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
CN109776657B (zh) * 2017-11-14 2021-11-26 北京康乐卫士生物技术股份有限公司 重组诺如病毒vlp颗粒和制备方法及其用途
MX2020005530A (es) 2017-11-30 2021-01-15 Medicago Inc Proteinas vp1 de norovirus modificadas y psv que comprenden proteinas vp1 de norovirus modificadas.
CA3083953A1 (en) * 2017-12-11 2019-06-20 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
KR102803235B1 (ko) * 2018-06-04 2025-05-07 시아먼 유니버시티 타입 39 인유두종 바이러스 l1 단백질의 돌연변이체
KR102075393B1 (ko) * 2018-06-28 2020-02-11 한국과학기술원 중증 열성 혈소판 감소 증후군(sfts) 바이러스 감염 질환 예방 또는 치료용 백신 조성물
WO2020010428A1 (en) 2018-07-13 2020-01-16 Medicago Inc. Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
WO2020041192A1 (en) 2018-08-20 2020-02-27 Takeda Vaccines, Inc. Vlp formulations
AR117462A1 (es) * 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
JP7075130B2 (ja) * 2019-10-25 2022-05-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
CN114316033A (zh) * 2020-09-29 2022-04-12 香港理工大学深圳研究院 一种特异性识别诺如病毒的单克隆抗体及制备方法与应用
JP2024503274A (ja) * 2020-12-30 2024-01-25 遠大賽威信生命科学（南京）有限公司 ノロウイルスのウイルス様粒子、免疫組成物又はキット及びその用途
KR20240009995A (ko) * 2021-05-20 2024-01-23 덴카 주식회사 항노로바이러스 항체
US20240238401A1 (en) 2021-05-21 2024-07-18 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
US20240402174A1 (en) 2021-10-04 2024-12-05 Takeda Vaccines, Inc. Methods for determining norovirus-reactive antibodies
EP4499138A1 (en) * 2022-03-25 2025-02-05 Merck Sharp & Dohme LLC Controlled release vaccine formulations

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
JPH07509122A (ja) * 1992-04-08 1995-10-12 ザ　ガバメント　オブ　ザ　ユナイテッド　ステイツ　オブ　アメリカ，アズ　レプリゼンテッド　バイ　ザ　セクレター，デパートメント　オブ　ヘルス　アンド　ヒューマン　サービシーズ 野生型麻疹ウイルス糖タンパク質：ワクチンおよびその検出方法
AU4851493A (en) 1992-09-07 1994-03-29 Baylor College Of Medicine Methods and reagents to detect and characterize norwalk and related viruses
US5788970A (en) * 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
BR9507657A (pt) * 1994-05-16 1997-09-09 Merck & Co Inc Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte
US5645051A (en) * 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) * 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5953727A (en) * 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
CA2288129A1 (en) * 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) * 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
BR9913026A (pt) * 1998-08-14 2001-09-25 Merck & Co Inc Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano
CA2354444A1 (en) * 1998-12-17 2000-06-22 Merck & Co., Inc. Synthetic virus-like particles with heterologous epitopes
KR100771402B1 (ko) 1999-06-22 2007-10-30 국립감염증연구소장이 대표하는 일본국 Ｓｒｓｖ 검출 킷트
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
WO2003068933A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
PL375306A1 (en) * 2002-06-20 2005-11-28 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
WO2005032457A2 (en) 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants
WO2005030806A2 (en) 2003-09-24 2005-04-07 Montana State University Norovirus monoclonal antibodies and peptides
US7795242B2 (en) * 2003-10-15 2010-09-14 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) * 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) * 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
JP4993301B2 (ja) 2004-10-20 2012-08-08 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US8168771B2 (en) * 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
US7767212B2 (en) 2005-03-18 2010-08-03 Cytos Biotechnology Ag CAT allergen conjugates and uses thereof
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
JP4825958B2 (ja) * 2005-08-10 2011-11-30 財団法人ヒューマンサイエンス振興財団 高リスク群ヒトパピローマウイルスの中和抗体を誘導する抗原
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
JP2007145775A (ja) * 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
HUE032422T2 (en) 2006-09-29 2017-09-28 Takeda Vaccines Inc Norovirus vaccine preparations
US20100266636A1 (en) * 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
SG10201601660YA (en) * 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
AU2009279456B2 (en) 2008-08-08 2015-02-05 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
SG182636A1 (en) * 2010-01-21 2012-08-30 Ligocyte Pharmaceuticals Inc Targeted heterologous antigen presentation on calicivirus virus-like particles

Also Published As

Publication number Publication date
NO2324113T3 (enExample) 2018-07-28
JP6448445B2 (ja) 2019-01-09
JP2011530295A (ja) 2011-12-22
EP2324113A1 (en) 2011-05-25
EP3382011A1 (en) 2018-10-03
DK2324113T3 (en) 2018-04-16
CN102177233B (zh) 2015-04-15
WO2010017542A1 (en) 2010-02-11
US8841120B2 (en) 2014-09-23
CN104911154A (zh) 2015-09-16
JP5852883B2 (ja) 2016-02-03
KR102118458B1 (ko) 2020-06-03
EP2324113A4 (en) 2012-01-04
AU2009279456A1 (en) 2010-02-11
CN102177233A (zh) 2011-09-07
SG2013057732A (en) 2015-02-27
AU2009279456A2 (en) 2011-03-31
US20150023995A1 (en) 2015-01-22
AU2009279456B2 (en) 2015-02-05
ES2668836T3 (es) 2018-05-22
CA2733589C (en) 2021-07-13
KR20110053994A (ko) 2011-05-24
JP2017153484A (ja) 2017-09-07
KR20170122848A (ko) 2017-11-06
CA2733589A1 (en) 2010-02-11
EP2324113B8 (en) 2018-04-04
KR101793161B1 (ko) 2017-11-03
JP2015171363A (ja) 2015-10-01
HK1215051A1 (zh) 2016-08-12
US9518096B2 (en) 2016-12-13
EP2324113B1 (en) 2018-02-28
US20110195113A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
SG2013057732A (en) Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
PL2635257T3 (pl) Cząstki wirusopodobne (vlp) glikoproteiny wirusa wścieklizny
IL254498A0 (en) Methods for preparing purified polypeptide preparations
IL215430A0 (en) Methods and compositions for immunization against virus
GB0822068D0 (en) Methods for virus design
IL207429A0 (en) A method of purifying a peptide
IL212786A (en) Peptides 4 - Amino - 4 - Oxo-Butanoyl as Viral Replication Inhibitors
PL2417251T3 (pl) Sposób oczyszczania wirusa wścieklizny
PT2099738T (pt) Procedimento para produção de polieteraminas
EP2267119A4 (en) PROCESS FOR VIRUS ENRICHMENT
ZA201102424B (en) Process for preparing 2-alkyl-3-aroyl-5-nitro-benzofurans
IL209919A0 (en) Process for preparing caspofungin and intermediates thereof
IL214375A0 (en) Novel peptides and methods for producing them
IL213416A0 (en) Process for the preparation of a peptide powder form
IL214257A0 (en) Peptides for vaccine
ZA201101645B (en) Process for prodcution of vaccines
IL209728A0 (en) Respiratory syncytial virus renders dendritic cells tolerogenic
EP2412704A4 (en) PROCESS FOR OBTAINING OPTICALLY PURE AMINO ACIDS
EP2374460A4 (en) SILDENAFIL COMPOSITION WITH PULSED RELEASE AND METHOD FOR PRODUCING THIS COMPOSITION
IL207222A0 (en) Process for preparing hebivolol
IL215183A0 (en) Process for preparing (r)-7v-benzyl-2-(benzyloxycarbonylamino)-s-methoxypropionamide
EP2501411A4 (en) PROCESS FOR IMPROVED ORAL ADMINISTRATION
GB0905515D0 (en) Radiolabelling methods
IL211996A0 (en) Process for the preparation of substituted phenylalanines
GB0714489D0 (en) Process for preparing viral vaccine